Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial [0.03%]
基于EMPEROR-Preserved临床试验在心力衰竭和射血分数保留的患者中应用恩格列净（JARDIANCE®）的公共卫生影响及成本效益分析研究法国患者
Laurent Fauchier,Nicolas Lamblin,Jean Tardu et al.
Laurent Fauchier et al.
Introduction: The efficacy and safety of empagliflozin in the treatment of heart failure with preserved ejection fraction (HFpEF) were demonstrated in the EMPEROR-Preserved trial, which showed a 21% reduction in combined ...
Healthcare Costs at the End of Life for Patients with Non-cancer Diseases and Cancer in Denmark [0.03%]
丹麦非癌症和癌症终末期患者的医疗费用
Anne Høy Seemann Vestergaard,Lars Holger Ehlers,Mette Asbjoern Neergaard et al.
Anne Høy Seemann Vestergaard et al.
Objectives: To examine costs of care from a healthcare sector perspective within 1 year before death in patients with non-cancer diseases and patients with cancer. ...
Disease Burden, Treatment Patterns, and Economic Impact of Rectovaginal Fistulas in Patients with Crohn's Disease: Findings from a Retrospective, Observational, Longitudinal Study Based on US Claims Databases [0.03%]
基于美国索赔数据库的回结阴道瘘克罗恩病患者的疾病负担、治疗模式和经济影响：一项回顾性观察性纵向研究发现
Chitra Karki,Dominick Latremouille-Viau,Inmaculada Gilaberte et al.
Chitra Karki et al.
Background: Crohn's-related rectovaginal fistulas (RVF) greatly impact quality of life and are notoriously difficult to treat. The aim of this study was to assess the burden of recurrent episodes of care for RVF and its e...
Correction: Cost-Effectiveness Analysis of Antimicrobial Prescribing in the Treatment of Clostridioides Difficile Infection in England [0.03%]
关于英格兰艰难梭菌感染抗菌药物处方成本效益分析的更正文章
Tom Bromilow,Hayden Holmes,Laura Coote et al.
Tom Bromilow et al.
Published Erratum
PharmacoEconomics - open. 2023 Sep;7(5):861. DOI:10.1007/s41669-023-00434-x 2023
Highly Purified Human Menopausal Gonadotropin (HP-hMG) Versus Recombinant Follicle-Stimulating Hormone (rFSH) for Controlled Ovarian Stimulation in US Predicted High-Responder Patients: A Cost-Comparison Analysis [0.03%]
高纯人绝经促性素与重组卵泡刺激素在美国预测的卵巢过度刺激综合症患者中成本比较分析
Andrew Khair,Tray Brown,Marie Markert et al.
Andrew Khair et al.
Objectives: Infertility imposes considerable clinical and economic burden, and the high costs of fertility care are a major barrier to payers. This study assessed the cost differences of highly purified human menopausal g...
A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico [0.03%]
与墨西哥其他基础胰岛素强化形式相比，IDegLira的相对控糖成本分析研究
Juan Carlos Garnica-Cuellar,Enrique Morales-Villegas,Carmen Alicia López-Forero et al.
Juan Carlos Garnica-Cuellar et al.
Objectives: Achieving glycemic control in patients with type 2 diabetes is important as it reduces the risk of complications and their related clinical and economic burden. Yet therapeutic inertia due to the fear of hypog...
Cost Effectiveness of Different Platelet Preparation, Storage, Selection and Dosing Methods in Platelet Transfusion: A Systematic Review [0.03%]
不同血小板制备、保存、选择和输注剂量方法的成本效益：一项系统综述
Jorien Laermans,Hans Van Remoortel,Hans Scheers et al.
Jorien Laermans et al.
Background and objective: Evidence-based guidelines on platelet transfusion therapy assist clinicians to optimize patient care, but currently do not take into account costs associated with different methods used during th...
Mapping the World Health Organization Disability Assessment Schedule (WHODAS 2.0) onto SF-6D Using Swedish General Population Data [0.03%]
利用瑞典人口数据将世界卫生组织残疾评估表（WHODAS 2. 0）映射到SF-6D上
Anna Philipson,Lars Hagberg,Liselotte Hermansson et al.
Anna Philipson et al.
Background and objective: Mapping algorithms can be used for estimating quality-adjusted life years (QALYs) when studies apply non-preference-based instruments. In this study, we estimate a regression-based algorithm for ...
Cost-Effectiveness Analysis of Antimicrobial Prescribing in the Treatment of Clostridioides Difficile Infection in England [0.03%]
英国抗生素处方治疗艰难梭菌感染的成本效益分析
Tom Bromilow,Hayden Holmes,Laura Coote et al.
Tom Bromilow et al.
Background: An economic model was developed with guidance from the National Institute for Health and Care Excellence (NICE) 'Managing Common Infections' (MCI) Committee to evaluate the cost effectiveness of different anti...
Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease [0.03%]
西妥昔单抗治疗特发性多中心卡斯特曼病的成本效益分析
Francis Shupo,Keith R Abrams,Zanfina Ademi et al.
Francis Shupo et al.
Objectives: This paper presents an Australian model that formed part of the health technology assessment for public investment in siltuximab for the rare condition of idiopathic Multicentric Castleman Disease (iMCD) in Au...